Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation provided an update on its patent litigation concerning the VASCEPA® (icosapent ethyl) capsule. The U.S. Court of Appeals upheld a ruling favoring two generic companies regarding their abbreviated new drug applications. Amarin plans to petition for an en banc review of this decision. Despite the setback, Amarin is pursuing additional regulatory approvals for VASCEPA in various international markets, including Europe and China, aiming for commercialization in early 2021. Amarin will maintain promotion efforts in the U.S. amidst expected limited generic competition.
Amarin Corporation presented significant findings at ESC Congress 2020 regarding VASCEPA, the first agent shown to induce coronary plaque regression in hypertriglyceridemic patients on statin therapy. The EVAPORATE trial revealed a 17% reduction in low attenuation plaque volume after 18 months of VASCEPA treatment. In the REDUCE-IT study, VASCEPA achieved statistical significance in reducing major adverse cardiovascular events across various patient subgroups. These results underscore VASCEPA's potential efficacy in mitigating cardiovascular risks and enhancing patient outcomes.
Amarin Corporation (NASDAQ:AMRN) announced positive results from the EVAPORATE trial, which evaluated the effects of VASCEPA on coronary plaque progression in patients treated with statins. The trial showed a significant 17% regression in low attenuation plaque (LAP) volume after 18 months compared with placebo. 80 patients participated, and although EVAPORATE was not powered for long-term outcomes, its findings reinforce VASCEPA's cardiovascular benefits demonstrated in the REDUCE-IT trial. While the study's sample size is a limitation, it provides valuable insights into VASCEPA's mechanisms.
Amarin Corporation announced new data on VASCEPA® (icosapent ethyl), to be presented at the ESC Congress 2020 from August 29 to September 1. Key presentations include the Late-Breaking Science session focusing on the EVAPORATE Study results, showing VASCEPA's effects on coronary atherosclerosis in patients on statin therapy. Other findings from the REDUCE-IT trials will also be shared, emphasizing data on ischemic events across different LDL cholesterol levels. This research underscores VASCEPA's potential in managing cardiovascular risks.
Amarin Corporation plc (NASDAQ:AMRN) has announced an investigator-initiated trial called MITIGATE COVID-19, which studies the effects of icosapent ethyl (VASCEPA) on viral upper respiratory infections, including COVID-19, in adults with atherosclerotic cardiovascular disease (ASCVD) at elevated risk. Sponsored by Kaiser Permanente Northern California, the trial will enroll 1,500 patients aged 50 and older. Participants will receive 4 grams per day of VASCEPA for at least six months. The study aims to evaluate the drug’s impact on severe viral infections and associated clinical outcomes.
Amarin Corporation plc (NASDAQ:AMRN) plans a dedicated launch of VASCEPA® in Europe, pending Marketing Authorization Application approval. The company anticipates a significant market opportunity for cardiovascular risk reduction, with over 80 million affected individuals in Europe. Amarin is set to retain most economic benefits from this venture. Regulatory exclusivity could protect VASCEPA for up to 11 years, with potential patent extensions to 2039. Karim Mikhail has been appointed as senior vice president, leading commercialization efforts, focusing on market access and physician education for VASCEPA.
Amarin Corporation has announced its plans for a focused commercial launch of VASCEPA in Europe, pending the approval of its Marketing Authorization Application (MAA) by the European Medicines Agency. The potential market opportunity is significant, with over 80 million people in Europe suffering from cardiovascular disease. Amarin anticipates a 10-11 year regulatory exclusivity period and has recently appointed Karim Mikhail as Senior Vice President to lead the launch efforts. The company believes it has sufficient resources to achieve positive cash flows from the product.
Amarin Corporation (NASDAQ: AMRN) reported Q2 2020 net revenue of $135.3 million, a 34% increase from Q2 2019, and H1 2020 revenue of $290.3 million, up 67%. Despite COVID-19 challenges, normalized prescriptions for VASCEPA increased by approximately 44%, with a year-to-date growth of 57%. The company is advancing plans for VASCEPA's approval in Europe, expecting a launch in early 2021. As of June 30, 2020, cash and investments totaled $611.3 million. However, SG&A expenses rose 26% due to sales force expansion. Amarin aims to boost VASCEPA awareness through a direct-to-consumer campaign.
Amarin Corporation (AMRN) announced significant findings from the REDUCE-IT study regarding its product, VASCEPA. The data revealed a 34% reduction in first coronary revascularization events and 36% reduction in total revascularizations, with sustained statistical significance achieved by 11 months. The study highlighted consistent reductions across various types of interventions, including elective and emergency procedures. These results support VASCEPA's potential to transform cardiovascular care for high-risk patients with elevated triglycerides.
Amarin Corporation plc (NASDAQ: AMRN) announced a conference call on August 4, 2020, at 7:30 a.m. ET to discuss its Q2 2020 financial results and provide an operational update. The call will follow the earlier release of its financial results and will be accessible via the investor relations section of Amarin's website or by telephone. A replay will be available for two weeks. Investors can submit questions until August 3, 2020, at 4:00 p.m. ET. Amarin focuses on developing therapeutics for cardiovascular health, with its lead product, VASCEPA®, available in several countries.